• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Sensing Technology Drives the Future of Medical Care

    New and Developing Diabetes Technologies Offer 'Sweet Relief'

    Discussing Matters of Substance in Medtech Materials

    Medical Device Testers Are Caught Up in a Whirlwind

    6 Ways ERP Systems Help Medical Device Manufacturers Manage Risk and Profitability
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    SurgVision's EXPLORER AIR II Gets FDA OK

    Brainomix's Flagship Stroke AI Imaging Software OK'ed

    Cue Health Nabs EUA for Molecular Mpox Test

    FDA Clears Viz.ai's AI Algorithm for Abdominal Aortic Aneurysm

    Etiometry's IVCO2 Index Receives EU, Health Canada Authorization
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Sensing Technology Drives the Future of Medical Care

    New and Developing Diabetes Technologies Offer 'Sweet Relief'

    Discussing Matters of Substance in Medtech Materials

    Medical Device Testers Are Caught Up in a Whirlwind

    6 Ways ERP Systems Help Medical Device Manufacturers Manage Risk and Profitability
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    CR-SOP Neurotechnology Helps to Achieve ‘Sound’ Sleep

    Inside the Hospital Value Analysis Committee

    Face Time: Why Getting Engineers Out of the Lab Is Good for Business

    Common Paratubing Pitfalls and How to Avoid Them

    During Times of Uncertainty, Create Business Value with an Optimized Workforce
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Fusion Biotec Inc.

    Forefront Medical Technology

    Halkey-Roberts Corporation

    Medbio LLC

    NDH Medical Inc.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    3D Printing Medical Devices Revolutionized Manufacturing

    5 Current Trends in Medical Device Security

    How Advanced Sensors Improve Design & Functionality of Respiratory Care Equipment

    Sourcing Silicone Parts: Injection Mold or 3D Print?

    Cybersecurity in Healthcare: Getting on the Right Track
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Fusion Biotec Inc.

    Forefront Medical Technology

    Halkey-Roberts Corporation

    Medbio LLC

    NDH Medical Inc.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    Medical Device Funding: Any Signs of Life?

    ...

    Medical Device Funding: Any Signs of Life?
    Ben Dunn, Managing Director, Covington Associates05.01.17
    One of the most concerning aspects of the recent financial boom has been the lack of funding for medical device companies. While the implications of this shortage of capital have an immediate impact on anyone involved in the medical device industry, the shortage will eventually affect our entire society due to our dependence on medical devices that enhance the quality of life. As with most problems, the dearth in funding has been driven by various factors, rather than one single cause. 

    Taunted by the proclamations of record amounts of available investor capital and cash on company balance sheets, medical device companies of all sizes seeking investments have found it difficult to leverage such financing. With numerous reports about large amounts of available capital and investors’ struggle to put that money to work, the medical device entrepreneur must feel like he or she exists in a parallel universe, because none of the capital has trickled down. Whether it is a Series A or dreaded Series B round—which some refer to as the “valley of death”—it has been difficult to get an investor’s attention, let alone to convince them to part with their money. These obstacles expose more troubling and far-reaching issues within the medtech industry, namely, the amount of money available to companies and the reasons funding has become so difficult to obtain.

    Unlike in past years, there is a record amount of capital currently available for investment. According to Bain & Company, there was more than $1.4 trillion of committed but undeployed capital in private equity funds at the end of 2016, and that number doesn’t even include the large amounts of capital controlled by family offices or government investment arms.
    Moreover, the National Venture Capital Association reports that healthcare-focused venture capital funds raised over $12 billion of new capital in 2016. Clearly, there is a tremendous amount of dry powder for investment.

    So where is the money going?

    Certainly not into medical devices. The different investor classes—private equity, venture capital, and corporate investors—are funneling dollars into non-medtech sectors. Private equity firms have focused their investments on more mature businesses with stable cash flows and historical earnings (the opposite of a typical device company profile) while venture capital firms, which back early-stage companies, have invested heavily in non-medical technology organizations. The firms that have remained in healthcare have gravitated to biotechnology companies and ignored the medical device sector. Corporate investors, flush with cash and demonstrating a more risk averse strategy, have focused their efforts on less risky acquisitions rather than making investments in young companies. Rather than take the risk of investing in an early-stage business, OEMs are content to wait for a company to develop and ultimately pay more to acquire the business.

    Charts 1 and 2 (based on data compiled by Silicon Valley Bank) show the decline in medical device financing as a percentage of total venture investments. In 2016, of the approximately $75 billion of venture capital invested, just over 5 percent went to medical device companies. That figure represents a relative decrease of more than 50 percent compared with 2010, when over 11 percent of venture investments went toward medical devices. The impact of this relative decline is evident upon a closer examination of 2016, a year in which the aggregate amount of medical device investment dropped by 25 percent (from 2015) to $3.9 billion and the number of investments fell to a five-year low at 511.



    There are several reasons for this abscondence from medical devices. The most fundamental explanation involves the principal of risk versus return. Investors prefer financial prospects that give them the greatest chance of returns with the least amount of risk. When compared to other sectors, capitalists consider medical device investments as less attractive on the risk versus return scale. The environment for new medical devices has become much more challenging in recent years. U.S. Food and Drug Administration (FDA) approvals have been less predictable and more time-consuming. Consequently, the longer regulatory process increases time to market and reduces an investor’s time-based rate of return. Even after successfully navigating the FDA gauntlet, medical device companies are not out of the woods yet, as reimbursement has become much more uncertain and tedious. Investors used to be confident about product marketability upon regulatory approval, but that strategy is no longer viable. Regulatory approval is not enough to guarantee success—the device must now also demonstrate that it will be reimbursed and support value-based healthcare initiatives. 

    Not surprisingly, the liquidity path for medical device companies has become much more difficult as well. The initial public offering (IPO) window has been only open a crack (with a limited number of companies going public), forcing investors to rely on an M&A exit for their liquidity. And while medtech M&A remains very active, there have been some unfavorable changes in recent years affecting investments. Perhaps the most troubling change is the challenging regulatory environment, which has increased the amount of time it takes for an acquisition to occur. Previously, an acquisition would quickly follow regulatory approval; now companies wait to determine the type of market traction for a product (due to reimbursement concerns) before merging. Accordingly, the longer time frame makes an investment less valuable and increases its risk.

    Another factor significantly impacting medtech financing is the consolidation among large medical device OEMs. These unions are reducing the number of potential buyers of businesses, leaving investors with fewer exit options and lower values. Medical device exits for VC-backed companies hit a three-year low in 2016, with the industry experiencing only three IPOs and 13 M&A transactions, according to Silicon Valley Bank. Exits for device companies are taking longer and occurring increasingly in later stages. Over the past three years, two-thirds of the companies with meaningful exits have been commercial stage while only 18 percent have been pre-approval stage, thereby increasing the average time to exit for medical device companies to more than eight years in 2016.

    The industry’s financial struggles become even more troubling when compared with the glut of biotechnology investments. As medical device companies fight to attract funding, biotechnology firms have attracted record amounts of funding seemingly with ease. Since 2010, annual investments in biotechnology have more than doubled, from less than $4 billion annually to just under $9 billion. While this disparity certainly is frustrating to medtech entrepreneurs, there are some important factors that have made the biotechnology sector more appealing. First and foremost, biotechnology has produced several impressive exits for investors. It almost seems as if an early-stage biotechnology company is being acquired on a weekly basis. There has also been a steady stream of IPOs providing both liquidity for investors and new potential buyers for startups. Finally, biotechnology firms are striking deals earlier in their lifecycle. Investors don’t even wait for regulatory approval anymore—phase 2 clinical results are often sufficient for buyers. An evaluation of large biotechnology exits over the past two years shows that more than half of the major exits occurred in companies that were either in the pre-clinical stage or had just completed phase I trials. Considering most medical device exits occurred after eight years and well into commercialization, it is easy to understand the allure of the biotechnology sector. 

    A Light at the End of the Tunnel?
    Those of us who have lived through a number of business cycles know the investment pendulum will eventually swing back to medical devices. The long-term fundamentals of this market remain too strong and the global need too great for investors to ignore. Sooner or later, the sectors currently in favor will begin to overheat, burning stakeholders and forcing them to seek new investment areas. Intrepid and contrarian financiers who anticipate this shift will reap the greatest rewards, as they will realize there are great returns awaiting in the medical device space. The lack of recent funding has left fewer startups with which to compete, increasing companies’ chances of success. In time, healthcare investors will naturally start to look for alternatives to informatics and biotechnology ventures, and when they change their focus, they’ll find a new breed of medical device startups. In this class will be companies that have developed capital-efficient models through the effective use of outsourced partners. These companies will also be managed by executives who take nothing for granted and understand their products must provide better clinical efficacy as well as greater societal value.

    Cause for optimism can be found upon closer evaluation of medical device investments last year. Series A investments reached a 10-year high of 60 companies in 2016, nearly doubling from the previous year’s total. This shift could potentially indicate that institutional investors may be looking more closely at medical device companies and are planting more seeds. One can only hope that investors will continue to nurture these promising young companies and not let them wither on the vine. 


    Ben Dunn is a managing director with Boston, Mass.-based Covington Associates. For more than 20 years, he has advised medical technology companies in the areas of mergers, acquisitions, investments, and strategic partnerships. Having advised clients on more than 100 transactions, Dunn has represented both private and public companies on both the buy and sell side. He is a frequent speaker at healthcare conferences and the author of numerous articles, including the whitepaper, “Medical Device Outsourcing Industry: Emerging Trends and Opportunities.” 
    Related Searches
    • change
    • Outsourcing
    • acquisition
    • quality
    Suggested For You
    MEDICAL & BIOTECH MANUFACTURING MEDICAL & BIOTECH MANUFACTURING
    Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles
    Accu-Tube Appoints Matthew Haddle as CEO Accu-Tube Appoints Matthew Haddle as CEO
    Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings
    CE Mark Granted to Predictive Software for Kidney Allograft Survival CE Mark Granted to Predictive Software for Kidney Allograft Survival
    Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech
    Precision Coating Merges with N2 Biomedical Precision Coating Merges with N2 Biomedical
    Medical Devices Market to Top $671.49 Billion by 2027 Medical Devices Market to Top $671.49 Billion by 2027
    Indago Announces $10 Million Financing Close and Name Change Indago Announces $10 Million Financing Close and Name Change
    Molli Surgical Molli Surgical's Breast Tumor Marker
    Vertigo Treatment Receives FDA Breakthrough Device Designation Vertigo Treatment Receives FDA Breakthrough Device Designation
    RapidPulse Closes $15 Million Series A Financing RapidPulse Closes $15 Million Series A Financing
    Midwest Products & Engineering Acquires MindFlow Design Midwest Products & Engineering Acquires MindFlow Design
    Vicarious Surgical Opens New Corporate Headquarters in Massachusetts Vicarious Surgical Opens New Corporate Headquarters in Massachusetts
    Luis J. Malavé Joins Integrity Applications Board Luis J. Malavé Joins Integrity Applications Board

    Related Literature / Brochures

    • MEDICAL & BIOTECH MANUFACTURING

      ISO 13485:2016 • FDA Registered

    • Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Neela Paykel is serving as general counsel and Tom Teisseyre assumes the chief product officer position.
      Business Wire 09.22.21

    • Tubing & Extrusion
      Accu-Tube Appoints Matthew Haddle as CEO

      Accu-Tube Appoints Matthew Haddle as CEO

      Haddle has a track record of leading organizations through strategic expansions across the medical device, aerospace, and industrial sectors.
      Accu-Tube 09.22.21


    • Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      The two deals will strengthen Heraeus' healthcare and medtech portfolio.
      Heraeus 09.22.21

    • CE Mark Granted to Predictive Software for Kidney Allograft Survival

      CE Mark Granted to Predictive Software for Kidney Allograft Survival

      Algorithm gives the probability the graft will still be functional at three, five, and seven years after evaluation by a healthcare professional.
      Cibiltech 09.21.21

    Loading, Please Wait..

    Trending
    • FDA Clears LiveMetric's Wearable Blood Pressure Monitoring Tech
    • The Future Of Biomedical Engineering Advancements
    • A New Approach To Post-Market Surveillance
    • Philips Names New Supervisory Board Chairman
    • J&J Exec Ashley McEvoy Named AdvaMed's New Chairman
    Breaking News
    • SurgVision's EXPLORER AIR II Gets FDA OK
    • Brainomix's Flagship Stroke AI Imaging Software OK'ed
    • Cue Health Nabs EUA for Molecular Mpox Test
    • FDA Clears Viz.ai's AI Algorithm for Abdominal Aortic Aneurysm
    • Etiometry's IVCO2 Index Receives EU, Health Canada Authorization
    View Breaking News >
    CURRENT ISSUE

    March 2023

    • Sensing Technology Drives the Future of Medical Care
    • New and Developing Diabetes Technologies Offer 'Sweet Relief'
    • Discussing Matters of Substance in Medtech Materials
    • Medical Device Testers Are Caught Up in a Whirlwind
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Nordic Naturals Debuts Probiotic Line in More Than 375 Sprouts Farmer’s Markets
    DolCas Biotech's Curcugen Featured in Beauty-From-Within Supplement
    NOW Tests Bromelain Supplements Purchased on Amazon
    Coatings World

    Latest Breaking News From Coatings World

    Norwegian Cruise Line Goes Biocide-Free with Nippon Paint Marine's AQUATERRAS
    ChemQuest Names Carla McBain a Director
    BASF Invests in Expansion of Polymer Dispersions Plant in Daya Bay, China
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    SurgVision's EXPLORER AIR II Gets FDA OK
    Brainomix's Flagship Stroke AI Imaging Software OK'ed
    Cue Health Nabs EUA for Molecular Mpox Test
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Diabeloop, Novo Nordisk Partner on Next-Gen Insulin Pens
    Jost Chemical Increases Manufacturing Capacity of Sodium Caprate, Sodium Caprylate
    Stevanato Group, Thermo Fisher Partner to Bring On-Body Delivery System to Market
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Mary Kay Earns Forest Stewardship Council Certification
    IPSY Teams Up with Anastasia Soare for Icon Box
    Tattoo Skincare Brand Mad Rabbit Raises $10 Million—Mark Cuban is an Investor
    Happi

    Latest Breaking News From Happi

    TheraBreath Launches Mouthwash Formulated for Kids
    Divi Appoints Erica Randerson Vice President of E-Commerce
    Past Estée Lauder Executive Joins Provectus Algae as Cosmetics Advisor
    Ink World

    Latest Breaking News From Ink World

    WestRock Holds Ground-Breaking on New Corrugated Box Plant in Washington
    MNYPIA Names John Hrdlick 2023 Anthony Mauriello Award Honoree
    Amcor’s Sustainability Commitment Receives ‘AA’ Rating by MSCI
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Jones Healthcare invests in Gallus Labelmaster from Heidelberg
    Innovia presents sustainable label films at Interpack
    Creation helps Whitworths with solvent-free flexible packaging prepress
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Kimberly-Clark Ranks Third Among 100 Most Sustainable Companies
    Weekly Recap: TerraCycle Launches Diaper Program, Ahlstrom to Divest or Shutter Stenay Plant & More
    Mativ Names CFO
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Loci Orthopaedics Earns New Patent for Thumb Base Joint Implant System
    Study: Running Does Not Increase Arthritis Risk
    Study Highlights the Positive Clinical Outcomes of Medacta’s MySpine System
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Retrofittable Electrochromic Films for Windows and Glass Facades
    Tekscan Launches New High-Speed Tire Pressure Testing System
    Schreiner PrinTrust Produces RFID-Enabled Labels for seventhings

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login